A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_E6692BB52E6C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer.
Journal
Nature cancer
Author(s)
Bobisse S., Bianchi V., Tanyi J.L., Sarivalasis A., Missiaglia E., Pétremand R., Benedetti F., Torigian D.A., Genolet R., Barras D., Michel A., Mastroyannis S.A., Zsiros E., Dangaj Laniti D., Tsourti Z., Stevenson B.J., Iseli C., Levine B.L., Speiser D.E., Gfeller D., Bassani-Sternberg M., Powell D.J., June C.H., Dafni U., Kandalaft L.E., Harari A., Coukos G.
ISSN
2662-1347 (Electronic)
ISSN-L
2662-1347
Publication state
Published
Issued date
10/2023
Peer-reviewed
Oui
Volume
4
Number
10
Pages
1410-1417
Language
english
Notes
Publication types: Clinical Trial, Phase I ; Journal Article
Publication Status: ppublish
Abstract
We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer. Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we show that such responses are further reinvigorated by subsequent adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells. The treatment is safe, and epitope spreading with novel neopeptide reactivities was observed after cell infusion in patients who experienced clinical benefit, suggesting reinvigoration of tumor-sculpting immunity.
Keywords
Humans, Female, Ovarian Neoplasms/therapy, Vaccines, Adoptive Transfer, Vaccination, T-Lymphocytes
Pubmed
Create date
25/09/2023 15:33
Last modification date
14/08/2024 6:17
Usage data